Meyka Pro banner
Belite Bio, Inc

Belite Bio, Inc (BLTE) Stock Overview

Explore Belite Bio, Inc’s financial performance, market position, analyst ratings, and future outlook.

BLTENASDAQ
HealthcareBiotechnology
$161.68
$2.81(1.77%)
U.S. Market opens in 14h 55m

Belite Bio, Inc (BLTE)

Meyka AI Score

Z

Key Financials

Market Cap6.5B
P/E Ratio-58.31
EPS (TTM)$-1.87
ROE-0.21%
Fundamental Analysis

AI Price Forecasts

1 Month$175.78
3 Months$222.54
1 Year Target$198.33

BLTE Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Belite Bio, Inc (NASDAQ: BLTE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Belite Bio, Inc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BLTE on the NASDAQ shows an RSI of 50.60, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $198.33 for the NASDAQ listing.

Key metrics behind Belite Bio, Inc's NASDAQ-traded stock include a P/E ratio of -58.31 and a market capitalization of 6.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BLTE on the NASDAQ.

Price Performance (NASDAQ: BLTE)

1-Day Change
1.77%
5-Day Change
-2.46%
1-Month Change
5.43%
3-Month Change
13.85%
6-Month Change
-14.02%
Year-to-Date (YTD) Change
1.08%
1-Year Change
154.13%
3-Year Change
377.92%
5-Year Change
1426.72%
All-Time (Max) Change
1426.72%

Contact Information

858-246-6240
12750 High Bluff Drive, San Diego, CA, 92130

Company Facts

410 Employees
IPO DateApr 29, 2022
CountryUS
Actively Trading

Frequently Asked Questions